![]() A connected and intelligent device, Tablo has two-way communication with the cloud, which allows treatment data to be sent electronically and enables physicians to remotely monitor patients so that they feel connected to their medical team while being comfortable at home. Outset offers the Tablo Hemodialysis System for kidney patients, a first-of-its-kind enterprise solution, FDA-cleared for use across the entire continuum of care - from hospital to home. "We are honored to be recognized for our growth and share this award with all of our employees, partners, patients, physicians and families who are on the journey with us to improve the lives of kidney patients everywhere." Tablo represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers," she said. "Dialysis is a huge expense and burden on patients and providers. Leslie Trigg, Chair and Chief Executive Officer of Outset, credits continued adoption of the company’s Tablo® Hemodialysis system in the acute and home markets with the company’s strong revenue growth in 2021. Outset revenue grew 5,000 percent to $103 million between 20. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, announced it ranked 33 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech and energy tech companies in North America, now in its 28 th year. SAN JOSE, Calif., November 16, 2022-( BUSINESS WIRE)-Outset Medical, Inc. ![]() Attributes 5,000 Percent Revenue Growth to Tablo® Hemodialysis System’s continued adoption in the acute and home settings
0 Comments
Leave a Reply. |